These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38979917)

  • 1. Components, Formulations, Deliveries, and Combinations of Tumor Vaccines.
    Liu T; Yao W; Sun W; Yuan Y; Liu C; Liu X; Wang X; Jiang H
    ACS Nano; 2024 Jul; 18(29):18801-18833. PubMed ID: 38979917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
    Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():615240. PubMed ID: 33679703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Strategies to Boost Cancer Vaccines.
    Li WH; Li YM
    Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
    Sayour EJ; Mendez-Gomez HR; Mitchell DA
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Vaccines, Adjuvants, and Delivery Systems.
    Paston SJ; Brentville VA; Symonds P; Durrant LG
    Front Immunol; 2021; 12():627932. PubMed ID: 33859638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and opportunities for cancer stem cell-targeted immunotherapies include immune checkpoint inhibitor, cancer stem cell-dendritic cell vaccine, chimeric antigen receptor immune cells, and modified exosomes.
    Alqarni A; Jasim SA; Altalbawy FMA; Kaur H; Kaur I; Rodriguez-Benites C; Deorari M; Alwaily ER; Al-Ani AM; Redhee AH
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23719. PubMed ID: 38764138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell vaccines.
    Thompson PL; Dessureault S
    Adv Exp Med Biol; 2007; 601():345-55. PubMed ID: 17713023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
    Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
    J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in Vaccine Therapies for Breast Cancer.
    Li X; Bu X
    Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
    Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
    Front Immunol; 2022; 13():936129. PubMed ID: 36059502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.